JP2010537961A5 - - Google Patents

Download PDF

Info

Publication number
JP2010537961A5
JP2010537961A5 JP2010522440A JP2010522440A JP2010537961A5 JP 2010537961 A5 JP2010537961 A5 JP 2010537961A5 JP 2010522440 A JP2010522440 A JP 2010522440A JP 2010522440 A JP2010522440 A JP 2010522440A JP 2010537961 A5 JP2010537961 A5 JP 2010537961A5
Authority
JP
Japan
Prior art keywords
seq
influenza
antigen
fluorocarbon vector
fluorocarbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010522440A
Other languages
English (en)
Japanese (ja)
Other versions
JP5756630B2 (ja
JP2010537961A (ja
Filing date
Publication date
Priority claimed from GBGB0716992.3A external-priority patent/GB0716992D0/en
Application filed filed Critical
Publication of JP2010537961A publication Critical patent/JP2010537961A/ja
Publication of JP2010537961A5 publication Critical patent/JP2010537961A5/ja
Application granted granted Critical
Publication of JP5756630B2 publication Critical patent/JP5756630B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010522440A 2007-08-31 2008-08-29 インフルエンザ抗原送達用のベクターおよび構築体 Expired - Fee Related JP5756630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0716992.3A GB0716992D0 (en) 2007-08-31 2007-08-31 Influenza antigen delivery vectors and constructs
GB0716992.3 2007-08-31
PCT/GB2008/002930 WO2009027688A1 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013123602A Division JP2013241414A (ja) 2007-08-31 2013-06-12 インフルエンザ抗原送達用のベクターおよび構築体

Publications (3)

Publication Number Publication Date
JP2010537961A JP2010537961A (ja) 2010-12-09
JP2010537961A5 true JP2010537961A5 (cg-RX-API-DMAC10.html) 2012-06-28
JP5756630B2 JP5756630B2 (ja) 2015-07-29

Family

ID=38617093

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010522440A Expired - Fee Related JP5756630B2 (ja) 2007-08-31 2008-08-29 インフルエンザ抗原送達用のベクターおよび構築体
JP2013123602A Pending JP2013241414A (ja) 2007-08-31 2013-06-12 インフルエンザ抗原送達用のベクターおよび構築体
JP2016041049A Withdrawn JP2016155829A (ja) 2007-08-31 2016-03-03 インフルエンザ抗原送達用のベクターおよび構築体
JP2017250464A Expired - Fee Related JP6826027B2 (ja) 2007-08-31 2017-12-27 インフルエンザ抗原送達用のベクターおよび構築体
JP2020160511A Pending JP2021001216A (ja) 2007-08-31 2020-09-25 インフルエンザ抗原送達用のベクターおよび構築体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013123602A Pending JP2013241414A (ja) 2007-08-31 2013-06-12 インフルエンザ抗原送達用のベクターおよび構築体
JP2016041049A Withdrawn JP2016155829A (ja) 2007-08-31 2016-03-03 インフルエンザ抗原送達用のベクターおよび構築体
JP2017250464A Expired - Fee Related JP6826027B2 (ja) 2007-08-31 2017-12-27 インフルエンザ抗原送達用のベクターおよび構築体
JP2020160511A Pending JP2021001216A (ja) 2007-08-31 2020-09-25 インフルエンザ抗原送達用のベクターおよび構築体

Country Status (22)

Country Link
US (4) US8642531B2 (cg-RX-API-DMAC10.html)
EP (2) EP2762164B1 (cg-RX-API-DMAC10.html)
JP (5) JP5756630B2 (cg-RX-API-DMAC10.html)
KR (3) KR101736897B1 (cg-RX-API-DMAC10.html)
CN (1) CN101827607A (cg-RX-API-DMAC10.html)
AR (1) AR068507A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008291974B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0815836A2 (cg-RX-API-DMAC10.html)
CA (1) CA2697729C (cg-RX-API-DMAC10.html)
CL (1) CL2008002559A1 (cg-RX-API-DMAC10.html)
CY (1) CY1115598T1 (cg-RX-API-DMAC10.html)
DK (2) DK2762164T3 (cg-RX-API-DMAC10.html)
EA (1) EA018765B1 (cg-RX-API-DMAC10.html)
ES (2) ES2488941T3 (cg-RX-API-DMAC10.html)
GB (2) GB0716992D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20140765T1 (cg-RX-API-DMAC10.html)
MX (1) MX2010002335A (cg-RX-API-DMAC10.html)
PL (1) PL2190474T3 (cg-RX-API-DMAC10.html)
PT (1) PT2190474E (cg-RX-API-DMAC10.html)
SI (1) SI2190474T1 (cg-RX-API-DMAC10.html)
TW (2) TW201345551A (cg-RX-API-DMAC10.html)
WO (1) WO2009027688A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
WO2012018907A2 (en) 2010-08-03 2012-02-09 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
JP6069212B2 (ja) * 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
EP2800576A2 (en) 2012-03-13 2014-11-12 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2015143339A2 (en) 2014-03-21 2015-09-24 University Of Washington Enhanced influenza hemagglutinin binders
WO2015157189A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
JP6103547B2 (ja) * 2015-01-09 2017-03-29 三菱電機株式会社 電子基板ユニット
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3257863A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Flourous metabolically stable peptide analogs
EP3257864A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Metabolically stable spexin peptide analogs
CN119033925A (zh) 2016-10-05 2024-11-29 Pds生物科技公司 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
US11517617B2 (en) 2017-09-08 2022-12-06 The University Of Melbourne Methods and compositions for preventing influenza infection
TW201924722A (zh) 2017-12-05 2019-07-01 美商Ｐｄｓ生技公司 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
JP2021520414A (ja) * 2018-04-04 2021-08-19 アルティミューン インコーポレーティッド Ｔ細胞を誘発するワクチン組成物の組合せ及びその使用
JP7037994B2 (ja) 2018-04-11 2022-03-17 株式会社シマノ 制御装置、人力駆動車、および制御方法
CN110772635B (zh) * 2019-11-11 2023-01-31 扬州大学 流感病毒小体包被的仿生纳米疫苗及其制备方法
EP4172897A1 (en) * 2020-06-29 2023-05-03 Seqirus UK Limited Adaptive vaccine stockpile
CN119306833B (zh) * 2023-07-11 2025-09-16 东莞市朋志生物科技有限公司 抗降钙素原抗体、检测降钙素原的试剂和试剂盒
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065141A (en) * 1960-08-24 1962-11-20 Albert E Gessler Separation of nucleoproteins and nucleic acids from aqueous protein mixtures
GB1193378A (en) 1967-04-11 1970-05-28 Rand Dev Corp Cancer Antigen Complexes
US3843443A (en) * 1973-03-30 1974-10-22 J Fishman Polypeptide materials bound to fluorocarbon polymers
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
US4689398A (en) * 1984-06-20 1987-08-25 Ortho Diagnostic Systems Inc. HTLV test using synthetic peptides
US4716102A (en) * 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
EP0252531B1 (de) * 1986-06-12 1992-12-02 BEHRINGWERKE Aktiengesellschaft Strukturelles Phosphoprotein (pp 150) des menschlichen Cytomegalovirus, seine Herstellung und Verwendung
EP0257758B1 (en) * 1986-08-07 1993-03-10 Minnesota Mining And Manufacturing Company Stable biologically active fluorochemical emulsions
US4954444A (en) 1987-03-02 1990-09-04 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5021551A (en) * 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6413516B1 (en) * 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US5817318A (en) * 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
CA2080835A1 (en) * 1990-04-18 1991-10-19 Jan H. Wong A 35kd tumor associated protein antigen and immune complex
AU658836B2 (en) * 1990-09-25 1995-05-04 Xenova Research Limited Viral defective vaccine produced by transcomplementing cell line
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
AU654481B2 (en) * 1991-03-14 1994-11-10 British Technology Group Usa, Inc. Recombinant anticoccidial vaccine
EP0503203A1 (en) 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Novel thrombin inhibitors
WO2003040165A2 (en) 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
EP0702563B1 (en) * 1993-05-27 2003-08-06 EntreMed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US6548046B1 (en) * 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6121123A (en) 1997-09-05 2000-09-19 Advanced Micro Devices, Inc. Gate pattern formation using a BARC as a hardmask
EP1023058A2 (en) 1997-10-24 2000-08-02 Alliance Pharmaceutical Corp. Amelioration of ischemic damage using synthetic oxygen carriers
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
EP1189624A4 (en) 1999-06-29 2005-02-23 Epimmune Inc Hla binding peptides and their uses
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
RU2218175C2 (ru) * 2001-03-06 2003-12-10 Научно-исследовательский институт по изучению лепры Способ стимуляции образования антител при иммунизации лабораторных животных
WO2002072627A2 (en) 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
JP2006512300A (ja) 2002-10-03 2006-04-13 エピミューン インコーポレイテッド Ｈｌａ結合ペプチド及びその使用
US20050013826A1 (en) 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
JP5260962B2 (ja) 2004-12-30 2013-08-14 インテル・コーポレーション 複数の命令シーケンサでのスレッド実行に基づく命令セットのためのメカニズム
FR2883563B1 (fr) 2005-03-24 2007-06-01 Ts Pharma Sarl Nouveaux vecteurs cationiques bolaformes hemifluorocarbones et leurs applications
PL2478916T3 (pl) * 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP1982992B1 (en) * 2006-02-07 2010-10-27 NEC Corporation Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation

Similar Documents

Publication Publication Date Title
Jiao et al. Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen
HRP20140765T1 (hr) Vektori i konstrukti za prijenos antigena gripe
JP7104096B2 (ja) 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
Stachyra et al. DNA vaccines against influenza
Müller et al. Inflammation, immunity, and vaccine development for Helicobacter pylori
AU7753191A (en) Oral vaccine comprising antigen surface-associated with red blood cells
Zhang et al. Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice
JP2004043496A (ja) ワクチンアジュバント
JP2014508783A (ja) 免疫系を調節するための免疫原性組成物およびその使用、疾患を治療および予防する方法、細胞再生を誘発する方法、ならびに免疫応答を更新する方法
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
JP2003526676A (ja) ワクチン用のアジュバント
BRPI0910036B1 (pt) kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina
Schülke et al. Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC
Niyomnaitham et al. Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
US20110256214A1 (en) Single-time vaccines
GB2467215A (en) Burkholderia thailandensis LPS vaccine
JP2017536823A (ja) 髄膜炎ｂワクチン
WO2008014570A2 (en) Treatment and prevention of allergic airways diseases
JP2001151697A (ja) 新規ワクチン組成物及び界面活性剤の免疫用アジュバントとしての使用
JP2019513797A (ja) シャーガスに関する抗原および抗体および組成物、それらの方法および使用
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination
US5882649A (en) Oral vaccine comprising antigen surface-associated with red blood cells
CN113185586A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用
EP4338749A1 (en) Vaccine against helicobacter pylori infection